• Brit Long and Alex Koyfman.
• Department of Emergency Medicine, Brooke Army Medical Center, Fort Sam Houston, Texas.
• J Emerg Med. 2019 Dec 1; 57 (6): 825-835.

BackgroundMalignancy predisposes patients to higher risk of venous thromboembolism (VTE), which is the second leading cause of death in patients with cancer.ObjectiveThis narrative review evaluates VTE in malignancy and the emergency medicine investigation and management of this patient population.DiscussionPatients with malignancy are at higher risk of VTE, including deep venous thrombosis (DVT) and pulmonary embolism (PE). Risk factors include the underlying cancer, other hematologic disorders, cancer therapies, and underlying comorbidities. While patients with malignancy and VTE can present similarly to those without malignancy, incidental VTE is more common in cancer patients. Existing scores such as the Wells and Revised Geneva score can assist in risk stratification in patients with malignancy. A negative D-dimer result in the appropriately risk-stratified patient can be used to exclude VTE, though D-dimer is more commonly elevated at baseline in patients with malignancy. Several scoring systems may be useful to predict recurrent risk of VTE, including the Khorana and Ottawa scores. Treatment includes anticoagulation with direct oral anticoagulants (DOACs) or low molecular weight heparin (LMWH). Outpatient therapy may be appropriate in select patients.ConclusionsThis narrative review provides key updates in the assessment and management of cancer patients with VTE.Published by Elsevier Inc.

22 keywords...

hide…